Limits...
Sulodexide for the Prevention of Recurrent Venous Thromboembolism: The Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.

Andreozzi GM, Bignamini AA, Davì G, Palareti G, Matuška J, Holý M, Pawlaczyk-Gabriel K, Džupina A, Sokurenko GY, Didenko YP, Andrei LD, Lessiani G, Visonà A, SURVET Study Investigato - Circulation (2015)

Bottom Line: Major or clinically relevant bleeding was the primary safety outcome.Adverse events were similar in the 2 groups.Sulodexide given after discontinuation of anticoagulant treatment reduced the risk of recurrence in patients with unprovoked venous thromboembolism, with no apparent increase of bleeding risk.

View Article: PubMed Central - PubMed

Affiliation: From Angiology Unit, University Hospital, Padua, Italy (G.M.A.); School of Specialization in Hospital Pharmacy, Department of Pharmaceutical Sciences, University of Milan, Italy (A.A.B.); Department of Medicine and Aging, "G. D'Annunzio" University, Chieti, Italy (G.D., G.L.); Cardiovascular Diseases, University of Bologna, Italy (G.P.); Angiologická Ambulance, Hodonín, Czech Republic (J.M.); Nemocnice České Budějovice-Interní Oddělení, České Budějovice, Czech Republic (M.H.); Department of Hypertensiology, Angiology and Internal Diseases, Medical University, Poznań, Poland (K.P.-G.); ALIAN s.r.o., Bardejov, Slovakia (A.D.); Federal State Institute, Nikiforov Russian Center of Emergency and Radiation Medicine, St. Petersburg, Russia (G.Y.S.); St. Petersburg State Medical Institution, City Multidisciplinary Hospital No. 2, Russia (Y.P.D.); Spitalul Clinic Judetean de Urgenta, Braşov, Romania (L.D.A.); and Angiology Unit, Hospital of Castelfranco Veneto, Italy (A.V.). gm.andreozzi@gmail.com.

Show MeSH

Related in: MedlinePlus

Risk of recurrence of venous thromboembolism in patients randomly assigned to sulodexide or placebo. A, Cumulative risk of recurrent venous thromboembolism. B, Results of an analysis of risk after adjustment for age, sex, index event (pulmonary embolism, or deep vein thrombosis), duration of anticoagulant therapy, and time from completion of anticoagulation therapy to randomization.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4643750&req=5

Figure 2: Risk of recurrence of venous thromboembolism in patients randomly assigned to sulodexide or placebo. A, Cumulative risk of recurrent venous thromboembolism. B, Results of an analysis of risk after adjustment for age, sex, index event (pulmonary embolism, or deep vein thrombosis), duration of anticoagulant therapy, and time from completion of anticoagulation therapy to randomization.

Mentions: The primary outcome, recurrence of VTE, occurred in 15 of the 307 patients who received sulodexide (4.9%; 95% CI, 2.9–8.1) compared with 30 of the 308 patients who received placebo (9.7%; 95% CI:, 6.8–13.7; hazard ratio, 0.49; 95% CI, 0.27–0.92; P=0.02; Figure 2A).


Sulodexide for the Prevention of Recurrent Venous Thromboembolism: The Sulodexide in Secondary Prevention of Recurrent Deep Vein Thrombosis (SURVET) Study: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.

Andreozzi GM, Bignamini AA, Davì G, Palareti G, Matuška J, Holý M, Pawlaczyk-Gabriel K, Džupina A, Sokurenko GY, Didenko YP, Andrei LD, Lessiani G, Visonà A, SURVET Study Investigato - Circulation (2015)

Risk of recurrence of venous thromboembolism in patients randomly assigned to sulodexide or placebo. A, Cumulative risk of recurrent venous thromboembolism. B, Results of an analysis of risk after adjustment for age, sex, index event (pulmonary embolism, or deep vein thrombosis), duration of anticoagulant therapy, and time from completion of anticoagulation therapy to randomization.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4643750&req=5

Figure 2: Risk of recurrence of venous thromboembolism in patients randomly assigned to sulodexide or placebo. A, Cumulative risk of recurrent venous thromboembolism. B, Results of an analysis of risk after adjustment for age, sex, index event (pulmonary embolism, or deep vein thrombosis), duration of anticoagulant therapy, and time from completion of anticoagulation therapy to randomization.
Mentions: The primary outcome, recurrence of VTE, occurred in 15 of the 307 patients who received sulodexide (4.9%; 95% CI, 2.9–8.1) compared with 30 of the 308 patients who received placebo (9.7%; 95% CI:, 6.8–13.7; hazard ratio, 0.49; 95% CI, 0.27–0.92; P=0.02; Figure 2A).

Bottom Line: Major or clinically relevant bleeding was the primary safety outcome.Adverse events were similar in the 2 groups.Sulodexide given after discontinuation of anticoagulant treatment reduced the risk of recurrence in patients with unprovoked venous thromboembolism, with no apparent increase of bleeding risk.

View Article: PubMed Central - PubMed

Affiliation: From Angiology Unit, University Hospital, Padua, Italy (G.M.A.); School of Specialization in Hospital Pharmacy, Department of Pharmaceutical Sciences, University of Milan, Italy (A.A.B.); Department of Medicine and Aging, "G. D'Annunzio" University, Chieti, Italy (G.D., G.L.); Cardiovascular Diseases, University of Bologna, Italy (G.P.); Angiologická Ambulance, Hodonín, Czech Republic (J.M.); Nemocnice České Budějovice-Interní Oddělení, České Budějovice, Czech Republic (M.H.); Department of Hypertensiology, Angiology and Internal Diseases, Medical University, Poznań, Poland (K.P.-G.); ALIAN s.r.o., Bardejov, Slovakia (A.D.); Federal State Institute, Nikiforov Russian Center of Emergency and Radiation Medicine, St. Petersburg, Russia (G.Y.S.); St. Petersburg State Medical Institution, City Multidisciplinary Hospital No. 2, Russia (Y.P.D.); Spitalul Clinic Judetean de Urgenta, Braşov, Romania (L.D.A.); and Angiology Unit, Hospital of Castelfranco Veneto, Italy (A.V.). gm.andreozzi@gmail.com.

Show MeSH
Related in: MedlinePlus